Celltrion opens world-first biosimilar symposium

Published: 2012-11-06 06:59:00

Updated: 2012-11-06 06:59:00

Celltrion, a local biopharmaceutical company, said Friday it held a launching symposium for its world’s first antibody biosimilar ‘Remsima’ at Millennium Hilton Hotel in Seoul.

Remsima is a biosimilar version of U.S. Merck’s Remicade, a globally renowned medication for rheumatoid arthritis.

In the symposium, Prof. Kim Ho-yeon of Catholic University said that Remsima may be widely used in...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.